Roche unruffled by China bill as it looks to grow roots in the region

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets.

Thomas Schinecker

“We’ve really worked on diversifying our supply chain and this is helping us now, so that we have multiple partners to work with across the world and we can absolutely adhere to those changes in legislation, should they come,” CEO Thomas Schinecker said on a media call.

In contrast, Novartis on Tuesday said it is working to shift its CRO collaborations “over time” to prepare for risks if Biosecure moves forward. The bill would prevent Chinese biotechnology companies “of concern” from doing business with US firms. Several biopharma companies have indicated they see regional manufacturing as a way to alleviate risks linked to the China bill.

In March, Roche Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks